Home Newsfeeds JP Morgan Downgrades Minerva Surgical to Underweight

JP Morgan Downgrades Minerva Surgical to Underweight

JP Morgan analyst Robbie Marcus downgrades Minerva Surgical (NASDAQ:UTRS) from Overweight to Underweight.

byBenzinga Newsdesk

August 10, 2022

1 minute read

JP Morgan analyst Robbie Marcus downgrades Minerva Surgical (NASDAQ:UTRS) from Overweight to Underweight.

Bsquare Announces Plans To Declassify Board

By Benzinga Newsdesk

October 18, 4:13 PM

Bsquare Corporation (NASDAQ:BSQR) (the "Company") announced today that it entered into a Cooperation Agreement (the "Agreement") with Richard ("Dick") Karp, a large shareholder. Pursuant to

BSQR

Analyst Ratings

8 Analysts Have This to Say About Autoliv

By Benzinga Insights

July 11, 2:04 PM

Autoliv (NYSE:ALV) has observed the following analyst ratings within the last quarter:

ALV

EXCLUSIVE: SciSparc’s Tourette Syndrome Candidate Receives IRB Approval To Start Phase 2b Study In US

By Vandana Singh

June 21, 8:30 AM

SciSparc Ltd (NASDAQ: SPRC) has received Institutional Review Board (IRB) approval for its Phase 2b clinical trial for SCI-110 in subjects suffering from Tourette Syndrome. Tourette Syndrome is a nervous system condition in which people have "tics."

SPRC

Avidity Biosciences And CleanSpark Were Among The 10 Biggest Mid-Cap Stock Gainers Last Week (June 9-June 15): Are These In Your Portfolio?

By Lekha Gupta

June 16, 2:25 PM

Top mid-cap performers: Avidity Biosciences, Iris Energy, Hims & Hers Health, John Wiley & Sons, Element Solutions, CleanSpark, Enovix Corp, Axcelis Tech, Intellia Therapeutics, Korn Ferry.

ACLS

JP Morgan Downgrades Minerva Surgical to Underweight

Related Posts

Bsquare Announces Plans To Declassify Board

8 Analysts Have This to Say About Autoliv

EXCLUSIVE: SciSparc’s Tourette Syndrome Candidate Receives IRB Approval To Start Phase 2b Study In US

Avidity Biosciences And CleanSpark Were Among The 10 Biggest Mid-Cap Stock Gainers Last Week (June 9-June 15): Are These In Your Portfolio?